William Blair restated their outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a research report report published on Thursday.

A number of other research firms also recently weighed in on DVAX. Royal Bank Of Canada set a $7.00 target price on Dynavax Technologies Corporation and gave the stock a hold rating in a research report on Wednesday, July 26th. Zacks Investment Research downgraded Dynavax Technologies Corporation from a buy rating to a hold rating in a research report on Tuesday, July 11th. Finally, ValuEngine downgraded Dynavax Technologies Corporation from a sell rating to a strong sell rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $23.67.

Dynavax Technologies Corporation (NASDAQ DVAX) traded up 72.97% on Thursday, reaching $16.00. The company had a trading volume of 21,723,800 shares. Dynavax Technologies Corporation has a 12 month low of $3.20 and a 12 month high of $17.50. The company’s market capitalization is $780.69 million. The company’s 50 day moving average price is $9.29 and its 200-day moving average price is $6.25.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.60). The company had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.75 million. Dynavax Technologies Corporation had a negative return on equity of 100.45% and a negative net margin of 1,080.18%. During the same quarter in the previous year, the company posted ($0.70) earnings per share. On average, equities analysts predict that Dynavax Technologies Corporation will post ($1.47) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “William Blair Reiterates Outperform Rating for Dynavax Technologies Corporation (NASDAQ:DVAX)” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/william-blair-reiterates-outperform-rating-for-dynavax-technologies-corporation-nasdaqdvax/1464503.html.

A number of large investors have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies Corporation during the first quarter worth approximately $121,000. Bank of America Corp DE increased its stake in Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares in the last quarter. CAPROCK Group Inc. bought a new stake in Dynavax Technologies Corporation during the second quarter worth approximately $134,000. American International Group Inc. increased its stake in Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 1,584 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in Dynavax Technologies Corporation during the second quarter worth approximately $158,000. Institutional investors and hedge funds own 54.94% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.